Telix Pharmaceuticals Shares Rise on Phase 3 Trial Completion and FDA Pathway Agreement

Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose significantly in premarket trading after the company announced it completed enrollment for its pivotal Phase 3 prostate cancer trial and reached an agreement with U.S. regulators on a path forward for approval.

Trial Progress and FDA Alignment

Telix confirmed it has finished enrolling 350 patients in its BiPASS trial. The study evaluates the effectiveness of the company's imaging agents, Illuccix and Gozellix, used in combination with an MRI, compared to the current standard of care for detecting prostate cancers.

Crucially, the company also announced it has aligned with the U.S. Food and Drug Administration (FDA) on a New Drug Application (NDA) pathway. According to Telix, this agreement, if the application is ultimately approved, would support reimbursement for the diagnostic as a new product and help broaden patient access.

Market Reaction and Analyst View

Following the news, Telix's American Depositary Receipts (ADRs) jumped 5.3% in premarket trading on Wednesday. The developments prompted analyst Robert Burns of H.C. Wainwright to reiterate a "Buy" rating and a $20.00 price target on the stock, according to an analyst note.

Ad

Burns highlighted the potential for Telix's product to address significant shortcomings in the current diagnostic process for prostate cancer. He noted that the company's less invasive and more precise option could be a preferred alternative to standard procedures.

Addressing Unmet Diagnostic Needs

The current diagnostic paradigm often involves invasive biopsies, even for patients considered low risk. According to the H.C. Wainwright note, these procedures can be painful, lead to complications, and may still fail to detect significant cancers.

Key statistics cited by the analyst underscore the market opportunity:

• More than 1 million prostate biopsies are performed in the U.S. annually.
• As many as 75% of these biopsies return a negative result.
• Approximately one in four patients refuse a recommended biopsy, indicating a desire for better alternatives.